Background and Purpose-Few data exist on the long-term outcomes of patients with spontaneous echo contrast (SEC), left atrial/left atrial appendage (LA/LAA) thrombus, and complex aortic plaque (CAP), in patients with atrial fibrillation receiving oral anticoagulation. We explored the relationship between these 3 echocardiographic findings and clinical outcomes, and the comparative efficacy and safety of apixaban and warfarin for each finding. Methods-Patients from the ARISTOTLE trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) with SEC, LA/LAA thrombus, or CAP diagnosed by either transthoracic or transesophageal echocardiography were compared with patients with none of these findings on transesophageal echocardiography. Results-A total of 1251 patients were included: 217 had SEC, 127 had LA/LAA thrombus, 241 had CAP, and 746 had none. The rates of stroke/systemic embolism were not significantly different among patients with and without these echocardiographic findings (hazard ratio, 0.96; 95% confidence interval, 0.25-3.60 for SEC; hazard ratio, 1.27; 95% confidence interval, 0.23-6.86 for LA/LAA thrombus; hazard ratio, 2.21; 95% confidence interval, 0.71-6.85 for CAP).
A thrombogenic milieu in the left atrium (LA) is an important factor in the pathogenesis of thromboembolic events in atrial fibrillation (AF). 1 It has been reported that the presence of spontaneous echo contrast (SEC) and LA thrombus, localized mainly in the LA appendage (LAA), may be predictors of stroke or systemic embolism in patients with AF. [2] [3] [4] [5] Complex aortic plaques (CAPs), coexisting with AF, might also increase the risk of thromboembolic stroke. 6, 7 However, there is a paucity of data on the relationship between these factors and long-term outcomes in patients with AF receiving oral anticoagulation. [2] [3] [4] [5] [6] [7] In the ARISTOTLE trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation), these echocardiographic risk factors were collected prospectively, providing a unique opportunity to assess the relationship between these findings and outcomes. 8 We explored the relationship between 3 echocardiographic findings (SEC, LA/ LAA thrombus, and CAP) and clinical outcomes, and the efficacy and safety of apixaban compared with warfarin for each finding. We hypothesized that patients with AF and at least 1 of these findings are not at increased risk of thromboembolic events when anticoagulated with either apixaban or warfarin and that apixaban has similar advantages over warfarin, with or without these echocardiographic findings. The second part of our hypothesis was suggested by previous analyses, in which efficacy and safety of apixaban compared with warfarin were consistent, regardless of the presence of valvular heart disease or left ventricular systolic dysfunction.
9,10

Methods
This is a secondary, post hoc analysis of the ARISTOTLE trial. The design and results have been published previously. 8, 11 ARISTOTLE was a double-blind, randomized trial comparing warfarin (target international normalized ratio, 2.0-3.0) with apixaban 5 mg twice daily (2.5 mg twice daily for patients with ≥2 of the following: age ≥80 years, body weight ≤60 kg, or serum creatinine ≥1.5 mg/dL) in patients with AF or flutter and at least 1 CHADS 2 risk factor (congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, stroke/transient ischemic attack) for stroke or systemic embolism. The median duration of followup was 1.8 years (1.4-2.3 years). This analysis included patients with SEC, LA/LAA thrombus (reported aggregately by the investigators), or CAP, diagnosed by either transthoracic or transesophageal echocardiography (TEE), both methods having a high sensitivity for the diagnosis of these echocardiographic findings. We compared these patients with those with none of these findings on TEE. We chose TEE because it has a high specificity for diagnosing SEC, LA/LAA thrombus, and CAP, and we wanted to ensure that those included in the control group had none of these echocardiographic findings. All echocardiographic data were systematically collected, as reported by the investigator. Echocardiographic examinations, either transthoracic or transesophageal, were performed before randomization by a median of 102 days (21-358 days). There was no central echocardiography laboratory. The study protocol was approved by institutional review boards or ethics committees at all participating sites, and all patients gave written informed consent before enrollment.
The primary efficacy outcome of ARISTOTLE was stroke or systemic embolism, and the primary safety outcome was major bleeding, as defined by the International Society on Thrombosis and Haemostasis criteria. 12 Secondary efficacy outcomes assessed for this analysis were ischemic stroke, myocardial infarction, cardiovascular death, and all-cause death. Functional outcome after stroke was assessed at discharge using the Rankin Scale, between 0 (no disability) and 6 (death). Secondary safety outcomes assessed were the composite of major or nonmajor clinically relevant bleeding (defined as bleeding not meeting the International Society on Thrombosis and Haemostasis definition for major bleeding but requiring change in therapy or extended hospitalization), intracranial bleeding, and any bleeding.
Statistical Analysis
Continuous variables are presented as medians and 25th and 75th percentiles; categorical variables are presented as counts and proportions. Patients with SEC, LA/LAA thrombus, or CAP were compared with those with no echocardiographic findings using the Wilcoxon rank-sum test for continuous variables and the χ 2 test for categorical variables. A Cox proportional hazards model was used to assess the effect of the 3 echocardiographic findings on outcomes. The unadjusted model included all 3 echocardiographic findings. The adjusted models included variables that were significantly different among the echocardiographic findings groups and thought to be associated with outcomes (see the online-only Data Supplement). Hazard ratios (HRs) and 95% confidence intervals (CIs) for each of the 3 echocardiographic findings are presented for the unadjusted and adjusted models. Event rates for outcomes are presented as rate per 100 patient-years of follow-up (total number of events). Three Cox proportional hazards models were used to assess the interaction between treatment effect and echocardiographic findings on the prespecified outcomes. HRs and 95% CIs are presented (apixaban versus warfarin) for each model. To assess the relationship between the Rankin Scale and each of the echocardiographic findings, we used percentage of patients with different levels of the scale (from 0 to 6) and we applied an exact CochranArmitage trend test between patients with and without each of the 3 echocardiographic findings. Differences with P values ≤0.05 (2-sided) were considered statistically significant. All analyses were performed at the Duke Clinical Research Institute (Durham, NC), using SAS version 9.4 (SAS Institute, Inc, Cary, NC).
Results
Patients
Of the 18 201 patients randomized in the ARISTOTLE trial, baseline echocardiographic data were available for 14 793 (of which 1055 had baseline TEE data). The current analysis included 1251 patients: 505 with at least 1 echocardiographic risk factor by either transthoracic echocardiography or TEE (217 cases of SEC, 127 cases of LA/LAA thrombus, and 241 cases of CAP), and 746 patients with none of these findings by TEE ( Figure 1 ; Table I in the online-only Data Supplement).
Baseline Characteristics
Compared with patients with no findings, patients with any 1 of the 3 echocardiographic findings were more often in persistent or permanent AF, had a greater prevalence of heart failure or reduced ejection fraction and left ventricular dysfunction, were more often treated with digoxin, and had more valvular heart disease ( Table 1 ). Patients with CAP had increased systolic and diastolic blood pressures, more prior myocardial infarction, and were more often treated with angiotensinconverting enzyme inhibitors or angiotensin receptor blockers and aspirin than those without any echocardiographic 
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December 2017 findings. Surprisingly, LA was not dilated in patients with either SEC or LA/LAA thrombus when compared with patients without these echocardiographic findings. The biomarkers NT-proBNP (N-terminal pro-B-type natriuretic peptide) and troponin I were both increased in patients with any of the echocardiographic findings.
Outcomes
Efficacy and safety outcomes according to the type of echocardiographic findings are presented in Table 2 and Figure 2 . 
Treatment Effect of Apixaban Versus Warfarin
For patients with either SEC or CAP, there was no evidence of a differential effect of apixaban over warfarin. For patients with LA/LAA thrombus, there was no significant interaction between apixaban and warfarin, with the exception of all-cause death (interaction P value=0.04) and any bleeding (interaction P value=0.03), where there was a greater benefit of apixaban compared with warfarin among patients with no LA/LAA thrombus compared with those with LA/LAA thrombus (Table 3 ).
Discussion
We showed that among anticoagulated patients with AF and at least 1 clinical risk factor for stroke, SEC, LA/LAA thrombus, and CAP do not seem to be associated with a higher risk of thromboembolic events.
Echocardiographic Risk Factors for Stroke
SEC is the result of ultrasound backscatter from slowly moving red blood cell aggregates. 1, 5, 13 Patients with AF and coexisting SEC might have increased frequency of LA/LAA thrombus, resulting in an increased risk for thromboembolic events. 1 Experimental studies showed that red blood cell-rich thrombi are resistant to fibrinolysis.
14 Similarly, clinical studies suggested that in patients with AF and concomitant SEC, endogenous fibrinolysis might be less effective, increasing the risk and the severity of stroke. 2, 5, 14 Previous studies suggested that patients with AF and LA/LAA thrombus have an increased risk of stroke, systemic embolism, and death ranging from 10% to 33% during 1 to 3 years of observation. 2, 3 The potential embolic risk of CAP detected by echocardiography was also shown in patients with AF and ischemic stroke. 2, 6 In the analysis of the 2 Possible explanations are related to blood flow abnormalities and a hypercoagulable state associated with AF, which might favor thrombogenesis in atria and atherosclerotic aorta. 15 Therefore, SEC, LA/LAA thrombus, and CAP are considered echocardiographic risk factors for thromboembolic events and death. This was demonstrated recently in a study of 103 patients with AF in which a multivariate logistic analysis, adjusted for age and CHADS 2 score of ≥2, found that these 3 echocardiographic factors were associated closely (odds ratio, 4.13-4.82) with the presence of silent brain infarction on magnetic resonance imaging; however, only 62% of these patients received oral anticoagulation. 16 There is very little published about the long-term outcomes of these factors in patients with AF using oral anticoagulation, as the studies of warfarin therapy vary from no anticoagulation 2, 3, 13 to use in less than half of patients. [4] [5] [6] 15 In our study, patients with various echocardiographic findings were diagnosed by either transthoracic echocardiography or TEE because both methods have a high sensitivity for the diagnosis of these echocardiographic risk factors 17 and our aim was to include all patients with these findings. Controls were selected by exclusion of all 3 of the echocardiographic findings by TEE because this method has a higher specificity than transthoracic echocardiography for the diagnosis of these findings 17 and our aim was to include in the control group only those with definite absence of these findings.
Effect of Anticoagulation
One prior small study assessed 43 patients with AF and LA thrombi. During a 3-year follow-up period, 72% of the thrombi disappeared, but 51% of the patients had a stroke or died. 18 However, during this observation period, the mean international normalized ratio was only 2.2±0.4. In a larger study of 295 patients with AF and a CHADS 2 score of 0 or 1, SEC and LA thrombus were not independent predictors of stroke or death, during a 5-year follow-up period, in anticoagulated patients with a median international normalized ratio of 2.4.
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To the best of our knowledge, our study is the largest analysis of outcomes in anticoagulated patients with AF and echocardiographic risk factors for stroke. Our results suggest that the risk of these echocardiographic findings may be neutralized by the use of anticoagulation with either apixaban or warfarin. This might have important clinical implications because patients with these echocardiographic findings may be inappropriately considered to be inadequately anticoagulated and might be postponed from undergoing cardioversion, even if they are on appropriate anticoagulation therapy. It is well demonstrated that oral anticoagulants do not act directly on lysis of old and stable LA/LAA thrombus, but they offer protection against embolic events by avoiding the generation of new thrombus. 18 As seen in other studies, patients in our analysis with echocardiographic findings were more often in persistent/permanent AF with a greater prevalence of valvular heart disease and heart failure/left ventricular dysfunction. 2, 14, 19 Patients with either LA/ LAA thrombus or CAP were more often anticoagulated before randomization. Both NT-proBNP and troponin I levels were increased at baseline in patients with any of the echocardiographic findings. Because it was demonstrated that these biomarkers are independently associated with an increased risk of stroke and death, 20, 21 we might speculate that in the absence of anticoagulation therapy these echocardiographic findings might be additional risk factors for thromboembolic events. 
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Limitations
There are several limitations to our study. This was an observational, post hoc analysis of the ARISTOTLE trial. We reported these 3 echocardiographic findings because these were the only echocardiographic findings systematically collected in ARISTOTLE. Data on influence of valvular heart disease or severity of left ventricular systolic dysfunction on outcomes have been reported previously. 9, 10 The echocardiographic findings were defined locally without a standardized core laboratory. However, this is the information that providers use in clinical decision making, and investigators were encouraged to use the current available guidelines for the diagnosis of these findings, so the observations are clinically relevant. The number of patients and events for each echocardiographic finding subgroup is relatively small, and, for example, the findings about CAP include the possibility of a modestly substantial association with risk of thrombosis. The median range of follow-up was 1.8 years (1.4-2.3 years), so events may not have been captured. Despite these limitations, this analysis is the largest outcome study in patients with these echocardiographic findings. Finally, the ARISTOTLE trial excluded patients with a CHADS 2 score of 0. However, a prior study showed that under oral anticoagulation, SEC or LA/LAA thrombus were not independent predictors of an increased risk of stroke or death even in patients with a low CHADS 2 score (0 or 1). Event rates presented as rate per 100 patient-years of follow-up (total no. of events). CAP indicates complex aortic plaque; CI, confidence interval; CRNM, clinically relevant nonmajor; HR, hazard ratio; LA, left atrial; LAA, left atrial appendage; MI, myocardial infarction; SE, systemic embolism; and SEC, spontaneous echo contrast.
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*P value for interaction between echocardiographic finding status and treatment arm.
Conclusions
In patients with AF and risk factors for stroke who are anticoagulated with apixaban or warfarin, the presence of SEC, LA/ LAA thrombus, or CAP does not seem to be associated with a higher risk of thromboembolic events. 
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